Abstract | AIM: MATERIALS AND METHODS: 39 adult patients with erythema multiforme were examined. The patients were split into groups based on therapy variant. One group (14 individuals) received Immunovac-VP-4 against the background of basic therapy; the other (12 individuals)--cagocel against the background of basic therapy; comparison group (13 individuals) received only basic therapy; 15 individuals composed a group of healthy individuals. All the patients had the level of pro-, anti-inflammatory and regulatory cytokines determined in blood sera by solid-phase EIA method by using Biosource (Austria) test-systems at the beginning of the study and after the therapy. RESULTS: In patients with exudative erythema multiforme Immunovac-VP-4 therapy facilitated a significant (p < 0.05) increase of serum IFN-gamma level, insignificant (p > 0.05) increase of IL-1beta and decrease of IL-17. Whereas cagocel lead to an increase of IL-4 (p > 0.05), IL-2, IFN-gamma (p < 0.05) and decrease of TGF-beta and IL-12 (p < 0.05). At the same time basic therapy facilitated a significant increase of IL-5 and decrease of IL-6, IL-12, IFN-gamma. CONCLUSION: Immunovac-VP-4 facilitates the increase of secretion of IFN-gamma, IL-1beta against the background of TGF-beta that facilitates normalization of cooperation of cells in immune response including against viral infections, and thereby influencing the trigger factor in EME patients.
|
Authors | E V Sorokina, N K Akhmatova, V G Khomenkov |
Journal | Zhurnal mikrobiologii, epidemiologii i immunobiologii
(Zh Mikrobiol Epidemiol Immunobiol)
2014 Jan-Feb
Issue 1
Pg. 36-41
ISSN: 0372-9311 [Print] Russia (Federation) |
PMID | 24738292
(Publication Type: Comparative Study, English Abstract, Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents
- Cytokines
- cagocel-1
- Gossypol
|
Topics |
- Adolescent
- Adult
- Anti-Inflammatory Agents
(administration & dosage)
- Cytokines
(blood, immunology)
- Erythema Multiforme
(blood, immunology, therapy)
- Female
- Gossypol
(administration & dosage, analogs & derivatives)
- Humans
- Immunotherapy
- Male
- Middle Aged
|